一、文章
1.Jun-Jie Li*,Wen-Juan Zhang*,Xiao-Hua Zeng*，Qing-Yuan Zhang*,Li Chen*,Jiong Wu,Guang-Yu Liu,Zhi-Hong Wang,Xiao-Bo Hu,Yan-Yan Hu,Zhen-Ling Li, and Zhi-Ming Shao*,Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial,J Clin Oncol,IF:44.5,DOI:10.1200/JCO-25-01153(2025)
2.Lei Fan*,Wen-Juan Zhang*,Hui-Ping Li*,Xiao-Hua Zeng*,Yue-E Teng*,Yue Gong*,Xi Jin,Shen Zhao,Tao Sun,Wen-Yan Chen,Shu-Sen Wang,Jin Yang,Zhi-Gang Zhuang,Su-Jie Ni,Zhi-Xian He,De-Yuan Fu,Chuan-Gui Song,Zheng Lv, Qian-Nan Liang,Bao-Hua Yu,Jing Shi,Nan Wang,Xin-Rui Liang,Ning-Ning Zhang,Yun Wang, Peng Ji,Xi-Yu Liu,Li Chen,Min He,Yin Liu,Xin-Yi Sui,Lin-Xiaoxi Ma,Xiu-Zhi Zhu,Fan Yang,Li-Ping Ge,Song-Yang Wu,Jiong Wu,1,2 Ke-Da Yu,Guang-Yu Liu,Xin Hu,Yu Shen,Zheng Pang,Jian-Fei Wang,Fei Liang,Wen-Tao Yang,Zhong-Hua Wang*,Yi-Zhou Jiang*, Zhi-Ming Shao*,Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2–breast cancer: The LINUXtrial，Cancer Cell, IF: 43.4,DOI:10.1016/j.ccell.2025.11.003(2025)
3.Zhang Ningning*,Shao Qing*,Xiang Xinni,Yan Chun,Tao Dan, Li Qian,Rong Huan,Zhao Yi,Xiang Tingxiu*,Zeng Xiaohua*，C1QL1 inhibits breast cancer through the HSP90α/VCP-ERS/UPR axis，Exp Mol Med,IF:12.9,DOI:10.1038/s12276-025-01486-1(2025)
4.JDongping Jiang，Senmiao Zhang，Ningning Zhang,Qing Shao，Guanwen Wang，Long Wang，Sisi Li，Yang Qin，Fanli Qu, Xiaohua Zeng *,Knowledge mapping of tumor microenvironment for breast cancer: a bibliometric analysis from2014to2023,FrontImmunol, 2025,16:1550988,IF:5.9,DOI:10.1002/jmri.29772(2025)
5.Guanwen Wang*,Ping Wen*,Ting Xue,Yuxin Huang,Qing Shao, Ningning Zhang,Fanli Qu,Jing Wang,Nan Wang*,Xiaohua Zeng*, Her2 promotes early dissemination of breast cancer by inhibiting the p38 pathway through the downregulation of MAP3K4. Cell Communication and Signaling,2024,22(1): 611,IF:8.2,DOI: 10.1186 /s12964-024-02000-2.
6.Ningning Zhang,Yuxin Huang,Guanwen Wang,Yimei Xiang, Zhouhong Jing,Junjie Zeng,Feng Yu,Xianjun Pan,Wenqi Zhou, Xiaohua Zeng*,Metabolomics Assisted by Transcriptomics Analysis to Reveal Metabolic Characteristics and Potential Biomarkers Associated with Treatment Response of Neoadjuvant Therapy with TCbHP Regimen in HER2+ Breast Cancer. Breast Cancer Research,Breast Cancer Res,2024,26(1):64,IF:7.4,DOI: 10.1186/s13058-024-01813-w.
7.Wenqi Zhoua,Yeli Yuea,Jing Xionga,Wei Lia,Xiaohua Zeng*, The role of locoregional surgery in de novo stage IV breast cancer: A meta-analysis of randomized controlled trials,Cancer TreatmentReviews,IF:10.9,DOI:10.1016/j.ctrv.2024.10278.
8.Ningning Zhang,Yimei Xiang,Qing Shao,Jing Wu,Yumin Liu, Hua Long,Dan Tao,Xiaohua Zeng*,Different risk and prognostic factors for liver metastasis of breast cancer patients with de novo and relapsed distant metastasis in a Chinese population, Front Oncol,IF:5.738,DOI:10.3389/fonc.2023.1102853.
9.Jing Wu,Yudi Jin,Mei Liu,Ningsheng Zhu,Zhouhong Jing, Xiaohua Zeng*,Recurrent Metaplastic Breast Cancer with Subtype Converted from Triple-Negative to HER2-Positive: A Case Report and Literature Review,BREAST CANCER-TARGET AND THERAPY,IF: 5.088,DOI:10.2147/BCTT.S395944.
10.Xuemei Yao,Wei Li,Liqi Li,Menghuan Li,Youbo Zhao,De Fang, Xiaohua Zeng* and Zhong Luo*,YTHDF1 upregulation mediates hypoxia-dependent breast cancer growth and metastasis through regulating PKM2 to affect glycolysis,CELL DEATH 8& DISEASE
11.Ningning Zhang*,Dan Tao,Haike Lei,Qing Shao,Yumin Liu, Hua Long,Xiaohua Zeng*,HBV Infection Status Does Not Influence the Initial Metastatic Pattern and the Prognosis of Breast Cancer Patients with De Novo and Relapsed Metastatic Disease, Journal of Inflammation Research,IF:6.922,DOI:10.2147/JIR. S355301.
二、承担和参与的科学研究项目
[1]国家自然科学基金面上项目，FXYD1调控MAEA/DDX5轴抑制三阴性乳腺癌转移的机制与靶向干预策略研究(82573237)；项目负责人(2026.1-2029.12)
[2]重庆市科卫联合医学科研项目重点项目，HR+/HER2+乳腺癌化疗豁免新辅助治疗方案疗效、安全性和生物标志物的临床研究(2025 ZDXM029)；项目负责人(2025.1-2027.12）
[3]重庆市自然科学基金面上项目，FXYD1抑制乳腺癌的机制和临床意义研究（CSTB2024NSCQ-MSX0694）；项目负责人（2024.7-2027.6）
[4]重庆市技术创新与应用发展专项重点项目，AI+肿瘤精准诊疗关键技术研发与应用(CSTB2023TIAD-KPX0049-5)；分课题项目负责人(2023.11-2026.10)
[5]重庆市教委科学计划研究项目重点项目，乳腺癌抗HER-2多组学疗效预测模型的建立及其分子调控机制研究(KJZD-K202000104)；项目负责人(2020.7-2023.6)
[6]重庆市科卫联合医学科研项目，HER-2阳性乳腺癌新辅助治疗疗效与代谢组学变化的关联研究(2021MSXM085)；项目负责人(20 20.9-2022.8)
[7]重庆市科学技术局项目，HER2阳性乳腺癌新辅助治疗前后代谢网络变化及其敏感性差异分子机制研究（CQYC20200303137)；项目负责人(2021.1 -2023.12)
[8]重庆市科学技术局项目，ER-SASH1-VIM/IQGAP-E-cadherin信号级联作为雌激素作用的新的信号通路调节乳腺癌转移的机制研究（cstc2018jxjl0159）；项目负责人(2018.12 -2020.11)
三、专利
[1]一种医学护理用杀菌消毒装置，第六顺位，专利号ZL 2022 1 0514981.6，授权公告号CN 114904029 B，授权公告日2023.6.30
[2]Medical monitoring system and application,medical monitoring device and monitoring - alarming method，第四顺位，授权公告号CN 2021/07185，授权公告日2021.11.27
四、相关奖励与荣誉
[1] 2016年度项目《D6在乳腺癌发生发展中的作用机制》获重庆市医学金科技成果奖三等奖
[2]2009年度第十届全国乳腺癌大会暨第四届上海国际乳腺癌论坛优秀论文一等奖
[3]2003年度项目《急性胰腺炎微循环改变的研究》获重庆市医学科学研究三等奖
